Smith-Lemli-Opitz syndrome

Smith-Lemli-Opitz syndrome (SLO) is a rare inherited metabolic disorder characterized by impaired cholesterol synthesis in the body. The disorder is caused by a deficiency of the enzyme 7-reductase, which is involved in the biosynthesis of cholesterol. As a result of this disorder, patients with SLO have a variety of clinical manifestations, including intellectual disabilities, spinal and limb abnormalities, and specific facial changes. Many patients also have cardiovascular abnormalities, developmental delays, and growth problems. The syndrome has significant clinical implications due to its complexity and multisystem nature, requiring a careful approach to diagnosis and treatment.

History of the disease and interesting historical facts

Smith-Lemli-Opitz syndrome was first described in 1964, when doctors began observing groups of patients with characteristic signs and symptoms that alerted them to the possibility of a rare inherited disorder. In 1995, molecular biology research identified the disorder as a genetic disorder caused by mutations in the DHCR7 gene. This gene encodes an enzyme responsible for converting 7-dehydrocholesterol into cholesterol, which is directly related to the clinical manifestations of TLS. In the years since, research has been conducted to better understand the pathophysiology of the syndrome and its genetic basis, which has improved diagnostics and treatment approaches.

Epidemiology

Smith-Lemli-Opitz syndrome is a rare disorder, with prevalence varying in different populations. On average, the estimate is 1:20,000–1:50,000 live births. The disorder occurs with higher frequency in certain ethnic groups, such as Jewish Amish populations and some other isolated groups, where the incidence may reach 1:10,000. However, the overall prevalence of SLO remains low, making it difficult to diagnose and sometimes leading to misunderstandings in the interpretation of clinical symptoms. The difficulty is that many cases of the syndrome may remain undiagnosed due to lack of knowledge and awareness among both the medical community and families.

Genetic predisposition to this disease

Smith-Lemli-Opitz syndrome is an autosomal recessive disorder, meaning that a patient must inherit two copies of the mutant gene, one from each parent, to exhibit symptoms. The main gene involved in the disorder is DHCR7, which codes for the enzyme 7-reductase. More than 50 different mutations in this gene have been described, most of which are permanent and most of which are found only in certain populations. These mutations result in decreased enzyme activity and, as a result, inadequate cholesterol synthesis, which causes a variety of diseases. Screening for DHCR7 gene mutations is an important part of diagnosing the disorder.

Risk factors for the development of this disease

Smith-Lemli-Opitz syndrome is predominantly associated with heredity, and risk factors in most cases are related to the reproductive history of parents who are carriers of mutations. The main risk factors include:

• Family history of Smith-Lemli-Opitz syndrome or other hereditary disorders.
• The birth of children in families with consanguineous marriages, which increases the likelihood of transmitting recessive mutations.
• Interesting observations indicate that the presence of mutations in other genes involved in steroid metabolism may be associated with an increased risk of developing the syndrome.
• Environmental factors, although not direct triggers, may aggravate clinical manifestations if the patient already has a predisposition to the disease.

Diagnosis of this disease

Smith-Lemli-Opitz syndrome can present with a variety of clinical symptoms, and diagnosis often involves a multidisciplinary approach. The main symptoms that may appear include:

• Mental retardation.
• Problems with growth and development.
• Anomalies in the structure of the face and limbs.
• Cardiovascular anomalies.
• Disorders in the development of the genital organs.

Laboratory tests for diagnosis may include:

• Measurement of cholesterol and 7-dehydrocholesterol levels in the blood.
• Genetic testing to detect mutations in the DHCR7 gene.

Radiologic examinations (eg, ultrasound and x-ray) may be useful to detect structural abnormalities. Other diagnostic tests may be performed, such as imaging of organs to detect possible malformations. Differential diagnosis should include other systemic disorders associated with lipid metabolism and syndromes that have similar symptoms.

Treatment

Treatment of Smith-Lemli-Opitz syndrome requires a comprehensive approach aimed at managing symptoms and improving patients' quality of life. General treatment may include:

• Pharmacological treatment with statins to normalize cholesterol levels.
• Using specialized cholesterol supplements to improve overall health.
• Surgical treatment to correct anatomical abnormalities, such as cardiovascular abnormalities.
• Rehabilitation interventions including physical and occupational therapy to support skill development.

Symptomatic treatment may also include psychological support for the patient and his family, assistance with emotional development and education.

List of medications used to treat this disease

The following medications may be used as pharmacological treatment for Smith-Lemli-Opitz syndrome:

• Statins (eg, simvastatin, atorvastatin) – to lower cholesterol levels and improve its metabolism.
• Cholestatin is a drug aimed at improving plasma cholesterol levels.
• High-cholesterol diets and specific dietary supplements containing cholesterol.

The use of these drugs should be strictly individualized depending on the patient's condition and the presence of concomitant diseases.

Disease monitoring

Monitoring the condition of a patient with Smith-Lemli-Opitz syndrome plays a key role in disease management and includes regular observation of clinical symptoms and laboratory dynamics. Key stages of monitoring:

• Regular checks for cholesterol and 7-dehydrocholesterol levels.
• Assessment of physical and psychomotor development.
• Screening for complications including cognitive and cardiovascular disorders.

The prognosis for TLS syndrome can vary from mild to severe depending on the nature of the manifestations and the treatment provided. Complications may include exacerbation of concomitant pathologies, the need for surgical correction of anomalies, and concomitant syndromes.

Age-related features of the disease

Smith-Lemli-Opitz syndrome has a variable age of onset, but the main clinical features often become apparent in infancy.

• In newborns: development and growth are monitored, and structural anomalies are monitored.
• In children: Monitoring psychomotor development and early intervention are critical.
• In adolescents: changes in physical development and emotional difficulties are observed, questions of identity arise.

Adults may face challenges in integrating into society and this requires additional support and attention.

Questions and Answers

• What is Smith-Lemli-Opitz syndrome? Smith-Lemli-Opitz syndrome is a rare inherited disorder associated with impaired cholesterol synthesis, accompanied by multiple systemic abnormalities.
• How is the syndrome diagnosed? Diagnosis includes genetic testing, cholesterol testing, and a clinical examination for characteristic symptoms.
• What are the main symptoms of the disease? The main symptoms include mental retardation, abnormalities in appearance, growth problems and cardiovascular abnormalities.
• Can the syndrome be cured? There is no complete cure, but symptoms can be controlled with medication and other therapies.
• What is the prognosis for patients? The prognosis depends on the severity of the syndrome, the presence of concomitant diseases and the timeliness of the implementation of therapeutic intervention tasks.